SAB4200522

Anti-IDH1 (C-terminal) antibody produced in rabbit

~1.0 mg/mL, affinity isolated antibody

• Synonym(s): Anti-IDP, Anti-PICD, Anti-isocitrate dehydrogenase 1 (NADP+), soluble, IDH
• UNSPSC Code: 12352203
• NACRES: NA.41

Properties

• biological source: rabbit
• Quality Level: 200
• conjugate: unconjugated
• antibody form: affinity isolated antibody
• antibody product type: primary antibodies
• clone: polyclonal
• form: buffered aqueous solution
• mol wt: antigen ~45 kDa
• species reactivity: rat, mouse, human
• concentration: ~1.0 mg/mL
• technique(s): immunohistochemistry: 20 μg/mL using human kidney.; indirect immunofluorescence: 1-2 μg/mL using SHSY5Y cells.; western blot: 1-2 μg/mL using extracts of NIH3T3 cells and of rat cerebellum (S1 fraction).
• UniProt accession no.: O75874
• shipped in: dry ice
• storage temp.: −20°C
• target post-translational modification: unmodified
• Gene Information: human ... IDH1(3417) ; mouse ... Idh1(15926) ; rat ... Idh1(24479)

Description

General description

IDH1 is a cytoplasmic nicotinamide adenine dinucleotide phosphate (NADP⁺)-dependent enzyme, localized both in the cytoplasm and peroxisomes. The IDH1 gene is mapped to human chromosome 2q34. It comprises a tripeptide peroxisome targeting signal 1 in the C-terminal region and is majorly expressed in the liver.

Specificity

Anti-IDH1 (C-terminal)specifically recognizes human, rat and mouse IDH1.

Immunogen

synthetic peptide corresponding to a C-terminal sequence of human IDH1, conjugated to KLH. The corresponding sequence is highly conserved (single amino acid substitution) in rat and mouse IDH1.

Application

Anti-IDH1 (C-terminal) antibody produced in rabbit may be used in:

• immunoblotting
• immunofluorescence
• immunohistochemistry

Biochem/physiol Actions

Isocitrate dehydrogenase (IDH) is a key metabolic enzyme that catalyzes the oxidative decarboxylation of isocitrate into α-ketoglutarate (αKG) utilizing either nicotinamide adenine dinucleotide (NAD⁺) or nicotinamide adenine dinucleotide phosphate (NADP⁺) as co-substrates. Although the function and structure of IDH1 have been well characterized, it has only recently been implicated in cancer. IDH1 appears to have a tumor suppressor activity and its inactivation contributes to tumorigenesis partially mediated by induction of the hypoxia-inducible factor 1α (HIF1) pathway. A genome-wide mutation study has shown that IDH1 is mutated in glioblastoma, acute myeloid leukemia (AML) and chondrosarcoma. Mutations in IDH1 specific to Arg132 (R132) impart the enzyme the ability to generate 2-hydroxyglutarate (2HG) instead of αKG. Elevated levels of 2HG are correlated with increased risk of malignant brain tumors, and block cell differentiation by impairing histone demethylation. Several IDH1 mutations have been identified in gliomas, including R132H, R132C, R132S, R132G and R132L, each may result in different tumor type with varied malignant progression.

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Storage and Stability

For continuous use, storeat 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers,is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Disclaimer

Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class Code: 10 - Combustible liquids
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable